NASDAQ:MDXG MiMedx Group (MDXG) Stock Price, News & Analysis $5.94 0.00 (0.00%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$5.92 -0.02 (-0.34%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About MiMedx Group Stock (NASDAQ:MDXG) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get MiMedx Group alerts:Sign Up Key Stats Today's Range$5.86▼$6.0250-Day Range$5.81▼$7.4352-Week Range$5.47▼$10.14Volume1.99 million shsAverage Volume670,621 shsMarket Capitalization$877.34 millionP/E Ratio22.00Dividend YieldN/APrice Target$12.50Consensus RatingBuy Company OverviewMiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications. The company's products have applications in the areas of wound care, burn, surgical sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.Read More… MiMedx Group Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks76th Percentile Overall ScoreMDXG MarketRank™: MiMedx Group scored higher than 76% of companies evaluated by MarketBeat, and ranked 274th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingMiMedx Group has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageMiMedx Group has received no research coverage in the past 90 days.Read more about MiMedx Group's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth6.67% Earnings GrowthEarnings for MiMedx Group are expected to grow by 6.67% in the coming year, from $0.30 to $0.32 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MiMedx Group is 22.00, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 24.93.Price to Earnings Ratio vs. SectorThe P/E ratio of MiMedx Group is 22.00, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.27.Price to Book Value per Share RatioMiMedx Group has a P/B Ratio of 4.53. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about MiMedx Group's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.44% of the float of MiMedx Group has been sold short.Short Interest Ratio / Days to CoverMiMedx Group has a short interest ratio ("days to cover") of 7.7.Change versus previous monthShort interest in MiMedx Group has recently decreased by 3.66%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMiMedx Group does not currently pay a dividend.Dividend GrowthMiMedx Group does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.44% of the float of MiMedx Group has been sold short.Short Interest Ratio / Days to CoverMiMedx Group has a short interest ratio ("days to cover") of 7.7.Change versus previous monthShort interest in MiMedx Group has recently decreased by 3.66%, indicating that investor sentiment is improving. News and Social Media2.6 / 5News Sentiment0.68 News SentimentMiMedx Group has a news sentiment score of 0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.93 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for MiMedx Group this week, compared to 3 articles on an average week.Search Interest6 people have searched for MDXG on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added MiMedx Group to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, MiMedx Group insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,268,000.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 1.70% of the stock of MiMedx Group is held by insiders.Percentage Held by Institutions79.15% of the stock of MiMedx Group is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about MiMedx Group's insider trading history. Receive MDXG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MiMedx Group and its competitors with MarketBeat's FREE daily newsletter. Email Address MDXG Stock News HeadlinesMDXG MiMedx Group, Inc. - Seeking AlphaJune 29 at 5:05 PM | seekingalpha.comDirector Of MiMedx Group Makes $185K Buy - NasdaqJune 26, 2025 | nasdaq.comThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime. | Brownstone Research (Ad)Positive Signal: James L Bierman Shows Faith, Buying $185K In MiMedx Group StockJune 24, 2025 | benzinga.comDirector Of MiMedx Group Makes $185K BuyJune 24, 2025 | benzinga.comMIMEDX to Participate in Upcoming Investor ConferencesMay 27, 2025 | globenewswire.comMonday 5/5 Insider Buying Report: MDXG, HLMNMay 7, 2025 | nasdaq.comZooming In On MiMedx Group's EarningsMay 7, 2025 | finance.yahoo.comSee More Headlines MDXG Stock Analysis - Frequently Asked Questions How have MDXG shares performed this year? MiMedx Group's stock was trading at $9.62 at the beginning of the year. Since then, MDXG stock has decreased by 38.3% and is now trading at $5.94. View the best growth stocks for 2025 here. How were MiMedx Group's earnings last quarter? MiMedx Group, Inc (NASDAQ:MDXG) issued its earnings results on Wednesday, April, 30th. The company reported $0.06 earnings per share for the quarter, meeting analysts' consensus estimates of $0.06. The firm earned $88.21 million during the quarter, compared to analyst estimates of $86.32 million. MiMedx Group had a net margin of 11.40% and a trailing twelve-month return on equity of 22.70%. Read the conference call transcript. How do I buy shares of MiMedx Group? Shares of MDXG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of MiMedx Group own? Based on aggregate information from My MarketBeat watchlists, some other companies that MiMedx Group investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Hawkins (HWKN), Adobe (ADBE) and GE Aerospace (GE). Company Calendar Last Earnings4/30/2025Today6/30/2025Next Earnings (Estimated)7/30/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryMedical Equipment Current SymbolNASDAQ:MDXG CIK1376339 Webwww.mimedx.com Phone(770) 651-9100Fax678-384-6741Employees870Year FoundedN/APrice Target and Rating Average Stock Price Target$12.50 High Stock Price Target$13.00 Low Stock Price Target$12.00 Potential Upside/Downside+110.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)$0.27 Trailing P/E Ratio22.00 Forward P/E Ratio19.80 P/E GrowthN/ANet Income$42.42 million Net Margins11.40% Pretax Margin15.47% Return on Equity22.70% Return on Assets16.77% Debt Debt-to-Equity Ratio0.09 Current Ratio4.70 Quick Ratio4.13 Sales & Book Value Annual Sales$348.88 million Price / Sales2.51 Cash Flow$0.33 per share Price / Cash Flow17.93 Book Value$1.31 per share Price / Book4.53Miscellaneous Outstanding Shares147,700,000Free Float145,191,000Market Cap$877.34 million OptionableOptionable Beta1.83 20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free Report This page (NASDAQ:MDXG) was last updated on 6/30/2025 by MarketBeat.com Staff From Our PartnersWhy Is President Trump Fast-Tracking These Companies?Forget about AI… There's a hot new trend on Wall Street… And it's all thanks to President Trump. His ...InvestorPlace | SponsoredA new rule goes live in July — and the banks are quietly cashing inA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | Sponsored“Trump’s 24-Hour Profit Windows” revealedTrading legend Larry Benedict has discovered a repeating surge of $240 billion (and more)... Flowing into a...Brownstone Research | Sponsored379 passengers walked away from thisElon Musk just wrote a $51 million check to back this material’s next phase… Because it’s not just saving l...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MiMedx Group, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share MiMedx Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.